Literature DB >> 24513464

Clinical significance of late gadolinium enhancement in patients<20 years of age with hypertrophic cardiomyopathy.

Brandon M Smith1, Adam L Dorfman2, Sunkyung Yu3, Mark W Russell3, Prachi P Agarwal4, Maryam Ghadimi Mahani5, Jimmy C Lu2.   

Abstract

Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging is associated with adverse events in adults with hypertrophic cardiomyopathy (HC). However, limited data exist on the extent and clinical significance of LGE in the pediatric population. In 30 patients (aged 14.1±3.2 years) with clinically diagnosed HC who underwent cardiovascular magnetic resonance imaging from 2007 to 2012, segments with hypertrophy and LGE were identified by 2 experienced readers blinded to outcome. Radial, circumferential, and longitudinal strains were evaluated using feature tracking software. The composite outcome was defined as cardiac death, nonsustained ventricular tachycardia, ventricular fibrillation, or appropriate implantable cardioverter-defibrillator discharge. LGE was present in 17 of 30 patients (57%), all in a midmyocardial pattern, with median 3 segments per patient (interquartile range [IQR] 2 to 5). No LGE was detected in patients without phenotypic hypertrophy. Segments with LGE had decreased radial (basal segments 20.7% vs 70.9%, p=0.01), circumferential (basal segments -23.2% vs -29.3%, p=0.04), and longitudinal strains (basal segments -13.8% vs -20.9%, p=0.04). After median follow-up of 26.9 months (IQR 7.5 to 34.3), 7 patients who had an adverse outcome (5 ventricular tachycardia, 1 appropriate implantable cardioverter-defibrillator discharge, and 1 death) had more segments of LGE (median 4, IQR 2 to 7 vs 0, IQR 0 to 2, p=0.01). One patient without LGE had ventricular tachycardia on exercise test. In conclusion, LGE occurs in a similar pattern in pediatric patients with HC as in adults, associated with hypertrophy, decreased myocardial strain, and adverse clinical outcomes. Further longitudinal studies are necessary to evaluate the rate of development of LGE and relation to outcomes in a larger cohort.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24513464     DOI: 10.1016/j.amjcard.2013.12.034

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  18 in total

Review 1.  Utility of late gadolinium enhancement in pediatric cardiac MRI.

Authors:  Maryam Etesami; Robert C Gilkeson; Prabhakar Rajiah
Journal:  Pediatr Radiol       Date:  2015-12-30

2.  Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.

Authors:  Anna Axelsson Raja; Hoshang Farhad; Anne Marie Valente; John-Paul Couce; John Lynn Jefferies; Henning Bundgaard; Kenneth Zahka; Harry Lever; Anne M Murphy; Euan Ashley; Sharlene M Day; Mark V Sherrid; Ling Shi; David A Bluemke; Charles E Canter; Steven D Colan; Carolyn Y Ho
Journal:  Circulation       Date:  2018-08-21       Impact factor: 29.690

Review 3.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the Use of Cardiac Magnetic Resonance in Pediatric Congenital and Acquired Heart Disease: Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  Circ Cardiovasc Imaging       Date:  2022-06-21       Impact factor: 8.589

Review 4.  Society for Cardiovascular Magnetic Resonance/European Society of Cardiovascular Imaging/American Society of Echocardiography/Society for Pediatric Radiology/North American Society for Cardiovascular Imaging Guidelines for the use of cardiovascular magnetic resonance in pediatric congenital and acquired heart disease : Endorsed by The American Heart Association.

Authors:  Mark A Fogel; Shaftkat Anwar; Craig Broberg; Lorna Browne; Taylor Chung; Tiffanie Johnson; Vivek Muthurangu; Michael Taylor; Emanuela Valsangiacomo-Buechel; Carolyn Wilhelm
Journal:  J Cardiovasc Magn Reson       Date:  2022-06-21       Impact factor: 6.903

5.  Feature-tracking cardiac magnetic resonance method: a valuable marker of replacement fibrosis in hypertrophic cardiomyopathy.

Authors:  Nahid Rezaeian; Leila Hosseini; Negar Omidi; Mahya Khaki; Homa Najafi; Kianoosh Kasani; Mostafa Mousavizadeh; Yasaman Khalili; Mohammad Mehdi Hemmati Komasi; Yaser Toloueitabar; Sanaz Asadian
Journal:  Pol J Radiol       Date:  2022-05-16

6.  Calcific embolization with infective endocarditis involving the posterior mitral leaflet in a patient with underlying hypertrophic obstructive cardiomyopathy.

Authors:  Navneet Lather; Kyle Niziolek; Peter Toth; David M Harris
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

7.  Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.

Authors:  Soujanya Bogarapu; Michael D Puchalski; Melanie D Everitt; Richard V Williams; Hsin-Yi Weng; Shaji C Menon
Journal:  Pediatr Cardiol       Date:  2016-01-30       Impact factor: 1.655

8.  Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy.

Authors:  Heiner Latus; Kerstin Gummel; Karin Klingel; Axel Moysich; Markus Khalil; Nona Mazhari; Juergen Bauer; Reinhard Kandolf; Dietmar Schranz; Christian Apitz
Journal:  J Cardiovasc Magn Reson       Date:  2015-05-15       Impact factor: 5.364

9.  Reproducibility of Gadolinium Enhancement Patterns and Wall Thickness in Hypertrophic Cardiomyopathy.

Authors:  Gaston A Rodriguez-Granillo; Alejandro Deviggiano; Carlos Capunay; Macarena C De Zan; Patricia Carrascosa
Journal:  Arq Bras Cardiol       Date:  2016-06-10       Impact factor: 2.000

Review 10.  Childhood Hypertrophic Cardiomyopathy: A Disease of the Cardiac Sarcomere.

Authors:  Gabrielle Norrish; Ella Field; Juan P Kaski
Journal:  Front Pediatr       Date:  2021-07-02       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.